{
    "nct_id": "NCT03264989",
    "official_title": "A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis",
    "inclusion_criteria": "* Male and non-pregnant female patients 16-70 years of age (inclusive)\n* Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease genotypes are eligible.\n* Experienced at least 1 VOC within the preceding 12 months prior to Screening, as determined by medical history.\n* If receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to Screening\n* Hemoglobin ≥4.0 g/dL. Absolute neutrophil count ≥1.0 x 109/L and platelet count ≥75 x 109/L\n* Adequate renal and hepatic function as defined:\n* GFR ≥45 mL/min/1.73 m2 calculated by CKD-EPI\n* ALT ≤3 x ULN\n* Direct (conjugated) bilirubin ≤2 x ULN\n* ECOG performance status ≤2\n* Written informed consent (or assent/ parental consent for minor subjects) prior to any screening procedures\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* History of stem cell transplant.\n* Acute VOC ending 7 days prior to first dosing\n* Ongoing hospitalization prior to Screening\n* Received blood products within 30 days to first dosing\n* Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)\n* History of severe hypersensitivity reactions to other monoclonal antibodies\n* Received a monoclonal antibody or immunoglobulin -based agent within 1 year of Screening, or has documented immunogenicity to a prior biologic.\n* Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to Screening\n* Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)\n* Resting QTcF ≥470 msec at pretreatment (baseline) or other cardiac or cardiac repolarization abnormality",
    "miscellaneous_criteria": ""
}